Receiving a diagnosis of Chronic Myeloid Leukemia (CML) can be frightening, but it is important to understand that the management of this disease is one of the greatest success stories in modern ...
It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...
Easy as ABC: Managing Toxicities of Antibody-Drug Conjugates, Bispecific Antibodies, and CAR T-Cell Therapies The choice of frontline therapy for a patient with chronic phase chronic myeloid leukemia ...
The survival prognosis for patients with chronic phase CML has greatly improved since the introduction of TKIs, with some studies showing life expectancy close to the general population. Nonetheless, ...
Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b ...
Danziten, a nilotinib formulation, is approved for CML without mealtime restrictions, enhancing patient adherence and reducing cardiotoxicity risks. The drug offers equivalent efficacy to Tasigna, ...
Association of frailty with annual healthcare expenditures of older adults during cancer survivorship. This is an ASCO Meeting Abstract from the 2024 ASCO Quality Care Symposium. This abstract does ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results